Abstract
Hematological abnormalities including neutropenia, anemia, and thrombocytopenia are commonly seen in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. The aim of this study was to identify factors which would help to predict the development of hematological abnormalities in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. During a 4-year period, all patients with chronic hepatitis C started on treatment with pegylated interferon and ribavirin were identified. Patients were defined as having hematological abnormalities if they had the presence of either anemia, neutropenia, thrombocytopenia, or a combination of the above during treatment with pegylated interferon and ribavirin. A total of 136 patients with chronic hepatitis C were included in this study. Fifty-two (38.2%) of the patients developed significant hematological abnormalities during treatment with pegylated interferon and ribavirin with 28 (20.6%), 30 (22.1%), and 11 (8.1%) developed neutropenia, anemia, and thrombocytopenia, respectively. Genotype 1, history of hypertension, low baseline platelet count, low baseline hemoglobin, as well as a raised creatinine were significant factors associated with the development of hematological abnormalities. Significant hematological abnormalities are commonly present in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. This study identifies pretreatment parameters that may help identify high-risk patients who are more likely to develop hematological abnormalities during treatment for chronic hepatitis C.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lavanchy D (2009) The global burden of hepatitis C. Liver Int 29(Suppl 1):74–81
Hoofnagle JH (1997) Hepatitis C: the clinical spectrum of disease. Hepatology 26:15S–20S
Kew MC (1998) Hepatitis viruses and hepatocellular carcinoma. Res Virol 149:257–62
Yoshida H, Arakawa Y, Sata M et al (2002) Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 123:483–91
McHutchison JG, Ware JE Jr, Bayliss MS et al (2001) The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 34:140–7
Fried MW, Shiffman ML, Reddy KR et al (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–82
Manns MP, McHutchison JG, Gordon SC et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–65
McHutchison JG, Manns MP, Brown RS Jr et al (2007) Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 102:880–9
McHutchison JG, Manns M, Patel K et al (2002) Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123:1061–9
Reau N, Hadziyannis SJ, Messinger D et al (2008) Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol 103:1981–8
Mulhall BP, Younossi Z (2005) Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 39:S23
Ong JP, Younossi ZM (2004) Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 71(Suppl 3):S17–21
Kowdley KV (2005) Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 39:S3–8
www.rocheusa.com. Package insert Ribavirin.
Roche(Pegasys). Accessed from package insert.
PEGINTRON. Package insert.
Idrees M, Riazuddin S (2009) A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 9:5
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nachnani, J.S., Rao, G.A., Bulchandani, D. et al. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin. Ann Hematol 89, 121–125 (2010). https://doi.org/10.1007/s00277-009-0774-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-009-0774-y